Supernus Pharmaceuticals Inc.’s recently made public that its President, CEO Khattar Jack A. unloaded Company’s shares for reported $0.57 million on Feb 02. In the deal valued at $42.05 per share,13,532 shares were sold. As a result of this transaction, Khattar Jack A. now holds 804,142 shares worth roughly $ 30.23 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Then, Khattar Jack A. sold 300 shares, generating $12,602 in total proceeds. Upon selling the shares at $42.01, the President, CEO now owns 795,159 shares.
Before that, Khattar Jack A. sold 976 shares. Supernus Pharmaceuticals Inc. shares valued at $41,002 were divested by the President, CEO at a price of $42.01 per share. As a result of the transaction, Khattar Jack A. now holds 794,961 shares, worth roughly $29.88 million.
PT values the company’s stock at a premium of 16.47 to its Tuesday closing price. Jefferies also remained covering SUPN and has increased its forecast on April 13, 2021 with a “Buy” recommendation from previously “Hold” rating. Piper Sandler revised its rating on June 16, 2020. It rated SUPN as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of SUPN
On Tuesday, Supernus Pharmaceuticals Inc. [NASDAQ:SUPN] saw its stock fall -0.97% to $37.59. On the same session, the stock had its day’s lowest price of $37.49, but rose to a high of $38.21. Over the last five days, the stock has lost -3.17%. Supernus Pharmaceuticals Inc. shares have risen nearly 5.38% since the year began. Nevertheless, the stocks have risen 21.38% over the past one year. While a 52-week high of $42.09 was reached on 02/02/23, a 52-week low of $24.95 was recorded on 01/03/23. SMA at 50 days reached $38.89, while 200 days put it at $33.77. A total of 0.6 million shares were traded, compared to the trading of 0.33 million shares in the previous session.
Levels Of Support And Resistance For SUPN Stock
The 24-hour chart illustrates a support level at 37.32, which if violated will result in even more drops to 37.04. On the upside, there is a resistance level at 38.04. A further resistance level may holdings at 38.48. The Relative Strength Index (RSI) on the 14-day chart is 38.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.72, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.98%. Stochastics %K at 13.79% indicates the stock is a buying.
How much short interest is there in Supernus Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Supernus Pharmaceuticals Inc. stocks on Jan 12, 2023, growing by 0.61 million shares to a total of 5.53 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 4.92 million shares. There was a rise of 11.03%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 14.52% of the overall stock float, the days-to-cover ratio (short ratio) rose to 13.25.
Supernus Pharmaceuticals Inc. [SUPN] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 8,284,629 shares, or roughly 15.33% of the outstanding SUPN shares. In other words, the investor’s shares have risen by 519,988 from its previous 13-F filing of 7764641.0. Additionally, The Vanguard Group, Inc. increased 1.88% of its stake after which the total value it holdings stand at $233,914,724, while Armistice Capital LLC reduced -5.16% of its stake to hold $178.64 million in the firm. Over the last quarter, Macquarie Investment Management B purchased 50,966 shares of Supernus Pharmaceuticals Inc., while Dimensional Fund Advisors LP bought 112,865 shares. At present, SSgA Funds Management, Inc. is holding 1,885,400 shares valued at $77.32 million. Stephens Investment Management Gr owned 1,604,769 shares of the company at the time of its most recent 13F filing, worth $65.81 million.
According to FactSet, Supernus Pharmaceuticals Inc.’s share price will average $43.25 in the next year, based on opinions of analysts polled by the firm. This is up nearly 15.91 percent from its previous closing price of $37.96. Analysts expect Supernus Pharmaceuticals Inc. stock to reach the higher price of $47.00, while the lowest price estimate is $38.00. However, 4 analysts have rated SUPN stock as an Overweight in their predictions for 2023.